Overview A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients Status: Recruiting Trial end date: 2026-03-31 Target enrollment: Participant gender: Summary The study comprises two phases: phase I dose escalation (including PK run-in period and treatment period) and phase II study. Phase: Phase 1/Phase 2 Details Lead Sponsor: Shanghai Fosun Pharmaceutical Development Co, Ltd.